We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI) (CEASE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00796419
Recruitment Status : Terminated
First Posted : November 24, 2008
Results First Posted : April 28, 2017
Last Update Posted : April 28, 2017
Information provided by (Responsible Party):
Greg S. Martin, M.D., M.Sc., Emory University

Brief Summary:

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are similar conditions in which the lungs are critically injured by another inflammatory process in the body. Together they affect more than 150,000 people per year in the United States, with mortality approaching 50% and a financial burden estimated to exceed $5 billion. Fluid overload, weight gain, and reduced oncotic pressure (low blood proteins) are associated with prolonged need for mechanical ventilation and mortality in patients with ALI/ARDS. Historical studies have provided conflicting evidence for benefits with colloid or diuretic therapy in ALI/ARDS, but recent clinical trials have demonstrated significant improvements in blood oxygen levels. The mechanisms of these benefits are not yet certain, but appear to relate to albumin's (a protein medicine) specific ability to influence injury and inflammation in the lungs, thus improving the ability for the lung to repair and exchange oxygen.

The purpose of this project is to determine the effects of therapies that affect blood proteins on their ability to change the way the lungs and cardiovascular system (heart and blood vessels) function. Special measurements will be taken to understand how these protein medicines change the ability of the lung and whole body to recover from widespread injury, with additional measures of specific heart and lung function. This clinical trial randomizes ALI/ARDS patients with low blood protein levels to receive albumin (a natural blood protein that is known to influence inflammation) or hetastarch (a synthetic blood protein) with diuretic therapy targeted to improve respiratory function. Therapeutic effects on respiratory function and blood oxygen levels, extravascular lung water, oncotic pressure, lung fluid removal, and heart function will be characterized. This trial will advance our understanding of treatment of ALI/ARDS and the factors that affect fluid balance in the lungs of these patients.

Funding Source - FDA Office of Orphan Products Development (OOPD)

Condition or disease Intervention/treatment Phase
Lung Injury, Acute (ALI) Respiratory Distress Syndrome, Acute (ARDS) Drug: 5% human albumin Drug: 6% hetastarch Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury
Study Start Date : January 2009
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2016

Arm Intervention/treatment
Experimental: 1
Intravenous 5% human albumin
Drug: 5% human albumin
Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days

Experimental: 2
Intravenous 6% hetastarch
Drug: 6% hetastarch
Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days

Primary Outcome Measures :
  1. Change in Extravascular Lung Water (EVLW) [ Time Frame: Baseline to Day 5 (120 hours) ]
    Quantity of extravascular lung water (EVLW) measured by transpulmonary thermodilution. Higher measurements of EVLW per kilogram of body weight indicate increased lung injury. Normal values for EVLW are thought to be less than 10 mL/kg.

Secondary Outcome Measures :
  1. Change in Oxygenation (PaO2/FiO2 Ratio) [ Time Frame: Baseline, Day 1 ]
    Change in arterial oxygenation measured by arterial blood gas analysis. The partial pressure of O2 in arterial blood to fraction of inspired oxygen ratio (PaO2/FiO2) is a ratio of partial pressure arterial oxygen to fractional inspired inspired oxygen. This ratio is used as an indicator of hypoxemia (low blood oxygen). A PaO2/FiO2 ratio of 200-300 indicates mild ARDS, 100-200 indicates moderate ARDS, and less than 100 indicates severe ARDS.

  2. Ventilator-free Days [ Time Frame: Day 30 ]
    The 'ventilator free survival days' in a 30-day period is a previously validated method of comparing groups with respect to mechanical ventilator requirements while adjusting for mortality. This variable represents the number of days in the 30-day period following baseline that the patient is alive and not requiring mechanical ventilation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Consensus clinical definition of ALI or ARDS:

    • Partial pressure of oxygen in arterial blood to the fraction of inspired oxygen (PaO2 / FiO2) ratio ≤ 200 (ARDS) or ≤ 300 (ALI), and;
    • Bilateral infiltrates on chest x-ray, and;
    • No clinical evidence of congestive heart failure, and;
    • Pulmonary artery occlusion pressure (PAOP) ≤ 18 mm Hg, if a pulmonary arterial catheter is present
  • Serum total protein concentration < 6.0 g/dL.
  • Endotracheal intubation and mechanical ventilation ≥ 24 hours.

Exclusion Criteria:

  • Hemodynamic instability within the prior 24 hours: (either of the following)

    • Ongoing fluid resuscitation defined as > 2 liters of crystalloid boluses or > 4 units of blood products transfused in the prior 24-hour period.
    • Vasopressor support exceeding any of the following:
  • Dopamine or dobutamine > 5 mcg/kg/min, or in combination at any dose; or
  • Any other vasoactive agent (i.e. epinephrine, norepinephrine, phenylephrine)
  • Significant renal disease (either of the following at the time of screening):

    • End-stage renal disease, or
    • Renal insufficiency with serum creatinine ≥ 3.0 mg/dL or urine output < 500cc/24 hrs
  • Allergy to albumin, hetastarch or furosemide.
  • Increased risk for bleeding:

    • Within 72 hours of any surgical procedure requiring use of the operating room, or
    • Any current or previously diagnosed bleeding disorder, or
    • History of any intracranial abnormality (including, but not limited to, intracranial arteriovenous malformations, subdural/subarachnoid/intracerebral hemorrhage, intracranial mass lesions) or traumatic brain injury with Glasgow Coma Scal (GCS) < 9 in the prior 14 days, or
    • Prothrombin time international normalized ratio (INR) > 2.0, partial thromboplastin time (PTT) > 1.5 times control, platelet count < 50,000/cc3
  • Risk for worsening pulmonary edema due to systolic heart failure.
  • Technical pulse contour analysis limitations:

    • Absence of central venous catheter, clinical arterial vascular disease, severe hypothermia (core temperature < 94°F), weight < 40 kg or > 250 kg, clinically significant bleeding diathesis.
  • Failure of the patient or nearest relative to provide informed consent.
  • Refusal of the patient's attending physician to provide consent to participate.
  • Age < 18 years.
  • Pregnancy.
  • Inability to quantify urine output (e.g. absence of bladder or bladder catheter).
  • Significant hypokalemia (K+ < 3.5 meq/L), hypernatremia (Na+ > 155 meq/L) or hypomagnesemia (Mg < 1.0 meq/L)
  • Patient meets criteria for weaning mechanical ventilation:

    • Required FiO2 ≤ 0.40 and positive end-expiratory pressure (PEEP) ≤ 5, and;
    • Spontaneous tidal volumes > 5 ml / kg, and;
    • Spontaneous respiratory rate < 20 / minute, and;
    • Capable of spontaneous ventilation on continuous positive airway pressure (CPAP)=5, pressure support (PS)=5.
  • Expected survival ≤ 120 hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00796419

Layout table for location information
United States, Georgia
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
Emory Crawford Long Hospital
Atlanta, Georgia, United States, 30308
Emory University Hospital
Atlanta, Georgia, United States, 30322
United States, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Emory University
Layout table for investigator information
Principal Investigator: Greg S Martin, MD, MSc Emory University
Layout table for additonal information
Responsible Party: Greg S. Martin, M.D., M.Sc., Professor, Emory University
ClinicalTrials.gov Identifier: NCT00796419    
Other Study ID Numbers: IRB00002187
R01FD003440 ( U.S. FDA Grant/Contract )
622-2000 ( Other Identifier: Emory University )
First Posted: November 24, 2008    Key Record Dates
Results First Posted: April 28, 2017
Last Update Posted: April 28, 2017
Last Verified: March 2017
Keywords provided by Greg S. Martin, M.D., M.Sc., Emory University:
Acute lung injury (ALI)
Acute respiratory distress syndrome (ARDS)
Respiratory failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Lung Injury
Acute Lung Injury
Wounds and Injuries
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Thoracic Injuries
Hydroxyethyl Starch Derivatives
Plasma Substitutes
Blood Substitutes